ACAD
32.3
-0.1
-0.31%
AEMD
4.86
+0.04
+0.83%
APRI
0.534
-0.008
-1.5498%
ARNA
1.72
-0.05
-2.82%
ATEC
0.221
-0.018
-7.4276%
CNAT
2.87
+0.02
+0.70%
CRXM
0.19
0.00
0.00%
CYTX
0.32
-0.02
-5.88%
DXCM
64.38
-1.58
-2.40%
GNMK
5.91
-0.16
-2.64%
HALO
10.55
-0.29
-2.68%
ILMN
134.99
-0.76
-0.56%
INNV
0.092
-0.004
-4.167%
INO
10.48
-0.7
-6.26%
ISCO
3.75
-0.1
-2.60%
ISIS
57.56
0.00
0.00%
LGND
120.87
-2.25
-1.83%
LPTN
0.233
-0.009
-3.6349%
MBVX
0.72
0.00
-0.66%
MEIP
1.4
0.00
0.00%
MNOV
6.88
-0.1
-1.43%
MRTX
20.72
-0.32
-1.52%
MSTX
0.295
-0.006
-1.8279%
NBIX
45.58
-1.32
-2.81%
NUVA
52.94
-0.16
-0.30%
ONCS
1.96
+0.01
+0.51%
ONVO
2.72
-0.03
-1.09%
OREX
0.447
-0.02
-4.201%
OTIC
14.26
-0.36
-2.46%
QDEL
17.3
-0.38
-2.15%
RCPT
231.96
0.00
0.00%
RGLS
5.84
-0.32
-5.19%
RMD
55.8
-0.7
-1.24%
SPHS
1.2
0.00
0.00%
SRNE
6.86
-0.04
-0.58%
TROV
4.02
-0.14
-3.37%
VICL
0.399
+0.004
+1.013%
VOLC
18
0.00
0.00%
ZGNX
10.25
-0.38
-3.57%
ACAD
32.3
-0.1
-0.31%
AEMD
4.86
+0.04
+0.83%
APRI
0.534
-0.008
-1.5498%
ARNA
1.72
-0.05
-2.82%
ATEC
0.221
-0.018
-7.4276%
CNAT
2.87
+0.02
+0.70%
CRXM
0.19
0.00
0.00%
CYTX
0.32
-0.02
-5.88%
DXCM
64.38
-1.58
-2.40%
GNMK
5.91
-0.16
-2.64%
HALO
10.55
-0.29
-2.68%
ILMN
134.99
-0.76
-0.56%
INNV
0.092
-0.004
-4.167%
INO
10.48
-0.7
-6.26%
ISCO
3.75
-0.1
-2.60%
ISIS
57.56
0.00
0.00%
LGND
120.87
-2.25
-1.83%
LPTN
0.233
-0.009
-3.6349%
MBVX
0.72
0.00
-0.66%
MEIP
1.4
0.00
0.00%
MNOV
6.88
-0.1
-1.43%
MRTX
20.72
-0.32
-1.52%
MSTX
0.295
-0.006
-1.8279%
NBIX
45.58
-1.32
-2.81%
NUVA
52.94
-0.16
-0.30%
ONCS
1.96
+0.01
+0.51%
ONVO
2.72
-0.03
-1.09%
OREX
0.447
-0.02
-4.201%
OTIC
14.26
-0.36
-2.46%
QDEL
17.3
-0.38
-2.15%
RCPT
231.96
0.00
0.00%
RGLS
5.84
-0.32
-5.19%
RMD
55.8
-0.7
-1.24%
SPHS
1.2
0.00
0.00%
SRNE
6.86
-0.04
-0.58%
TROV
4.02
-0.14
-3.37%
VICL
0.399
+0.004
+1.013%
VOLC
18
0.00
0.00%
ZGNX
10.25
-0.38
-3.57%
Home » Bio: Jennifer Grodberg, PhD, RAC

Bio: Jennifer Grodberg, PhD, RAC

Jenny (Dr. Jennifer Grodberg) has over 19 years’ experience in the pharmaceutical industry. Currently she serves as Senior Director of Regulatory Affairs at Trius Therapeutics, a small pharmaceutical company developing antibacterial drugs for the treatment of infections caused by drug-resistant bacteria. Before working in regulatory affairs, she spent 10 years in anti-infectives drug discovery and technology/assay development, coordinating research programs from the identification of early drug leads through advancement to the IND enabling phase. Prior to entering the pharmaceutical industry, she held a faculty appointment at Harvard Medical School in the Department of Medicine. Jenny has a PhD in Microbiology, and completed post-doctoral work at both the Weizmann Institute of Science in Rehovot, Israel and Harvard Medical School. She obtained her RAC designation in 2007.
Jenny also serves as President of the American Medical Writers Association Pacific Southwest Chapter. This year she served as co-director of AMWA’s Pacific Regional Conference, and spent 2 years on the National organization’s executive committee as AMWA’s Annual Conference Workshop coordinator.